INSERM U1052-Cancer Research Center of Lyon (CRCL), 69008 Lyon, France; Department of Hepatology, Croix Rousse Hospital, Hospices Civils de Lyon, France; University of Lyon, UMR_S1052, CRCL, 69008 Lyon, France.
INSERM U1052-Cancer Research Center of Lyon (CRCL), 69008 Lyon, France; University of Lyon, UMR_S1052, CRCL, 69008 Lyon, France.
J Hepatol. 2017 May;66(5):897-909. doi: 10.1016/j.jhep.2016.12.024. Epub 2016 Dec 30.
BACKGROUND & AIMS: Hepatitis B virus (HBV) persistence and the pathobiology of chronic HBV (CHB) infections result from the interplay between viral replication and host immune responses. We aimed to comprehensively analyse the expression of intrahepatic host genes as well as serum and liver HBV markers in a large cohort of untreated CHB patients.
One-hundred and five CHB patients untreated at the time of liver biopsy (34 HBeAg[+] and 71 HBeAg[-]) were analysed for the intrahepatic expression profile of 67 genes belonging to multiple innate immunity pathways. Results were correlated to serological (quantification of HBsAg [qHBsAg] and HBV DNA) and intrahepatic viral markers (total HBV DNA, pre-genomic RNA and covalently closed circular HBV DNA).
Intrahepatic gene expression profiling revealed a strong downregulation of antiviral effectors, interferon stimulated genes, Toll-like and pathogen recognition receptor pathways in CHB patients as compared to non-infected controls, which was not directly correlated to HBV replication. A subset of genes [CXCL10, GBP1, IFITM1, IFNB1, IL10, IL6, ISG15, TLR3, SOCS1, SOCS3] was more repressed in HBeAg(-) respect to HBeAg(+) patients (median of serum HBV DNA 7.9×10vs. 7.9×10IU/ml, respectively). Notably, HBeAg(-) patients with lower qHBsAg (<5×10IU/ml) showed a relief of repression of genes belonging to multiple pathways.
Our results show a strong impairment of innate immune responses in the liver of CHB patients. The association of low levels of qHBsAg with gene repression, if confirmed, might prove useful for the identification of patients who would most benefit from immune-modulators and/or HBsAg targeting agents as strategies to restore immune responsiveness.
Chronic hepatitis B virus (HBV) infections represent a major public health problem worldwide. Over 200 million people are chronically infected and at risk of developing chronic hepatitis, liver cirrhosis and cancer. Our work aimed to understand the molecular consequences of chronic hepatitis B in the infected liver. It was conducted in a large cohort of untreated chronically infected HBV patients and analysed the expression of immunity and liver disease-related genes in the liver, with respect to markers of viral replication and persistence. Our results indicate that chronic HBV infection has a suppressive effect on immune responses, which was more pronounced with high levels of hepatitis B virus surface antigen (HBsAg). These data provide novel insight into the mechanisms of HBV persistence in the liver and suggest that approaches aimed at reducing HBsAg levels, may restore immune responsiveness against the virus.
乙型肝炎病毒(HBV)的持续存在和慢性乙型肝炎(CHB)感染的病理生物学是由病毒复制和宿主免疫反应之间的相互作用引起的。我们旨在全面分析未经治疗的 CHB 患者中大量患者的肝内宿主基因以及血清和肝 HBV 标志物的表达。
分析了 105 例未经肝活检治疗的 CHB 患者(34 例 HBeAg[+]和 71 例 HBeAg[-])的 67 种属于多种固有免疫途径的基因的肝内表达谱。结果与血清学(HBsAg[qHBsAg]和 HBV DNA 的定量)和肝内病毒标志物(总 HBV DNA、前基因组 RNA 和共价闭合环状 HBV DNA)相关。
与未感染对照相比,CHB 患者的抗病毒效应物、干扰素刺激基因、Toll 样受体和病原体识别受体途径的肝内基因表达谱显示出强烈下调,这与 HBV 复制没有直接关系。一组基因[CXCL10、GBP1、IFITM1、IFNB1、IL10、IL6、ISG15、TLR3、SOCS1、SOCS3]在 HBeAg(-)患者中比 HBeAg(+)患者受到更强的抑制(血清 HBV DNA 的中位数分别为 7.9×10和 7.9×10IU/ml)。值得注意的是,qHBsAg(<5×10IU/ml)较低的 HBeAg(-)患者表现出多种途径相关基因抑制的缓解。
我们的结果显示 CHB 患者肝内固有免疫反应受到强烈抑制。如果 qHBsAg 水平较低与基因抑制相关的结果得到证实,可能有助于确定最受益于免疫调节剂和/或 HBsAg 靶向药物的患者,这些药物可作为恢复免疫反应的策略。
背景与目的:乙型肝炎病毒(HBV)的持续存在和慢性乙型肝炎(CHB)感染的病理生物学是由病毒复制和宿主免疫反应之间的相互作用引起的。我们旨在全面分析未经治疗的 CHB 患者中大量患者的肝内宿主基因以及血清和肝 HBV 标志物的表达。
分析了 105 例未经肝活检治疗的 CHB 患者(34 例 HBeAg[+]和 71 例 HBeAg[-])的 67 种属于多种固有免疫途径的基因的肝内表达谱。结果与血清学(HBsAg[qHBsAg]和 HBV DNA 的定量)和肝内病毒标志物(总 HBV DNA、前基因组 RNA 和共价闭合环状 HBV DNA)相关。
与未感染对照相比,CHB 患者的抗病毒效应物、干扰素刺激基因、Toll 样受体和病原体识别受体途径的肝内基因表达谱显示出强烈下调,这与 HBV 复制没有直接关系。一组基因[CXCL10、GBP1、IFITM1、IFNB1、IL10、IL6、ISG15、TLR3、SOCS1、SOCS3]在 HBeAg(-)患者中比 HBeAg(+)患者受到更强的抑制(血清 HBV DNA 的中位数分别为 7.9×10和 7.9×10IU/ml)。值得注意的是,qHBsAg(<5×10IU/ml)较低的 HBeAg(-)患者表现出多种途径相关基因抑制的缓解。
我们的结果显示 CHB 患者肝内固有免疫反应受到强烈抑制。如果 qHBsAg 水平较低与基因抑制相关的结果得到证实,可能有助于确定最受益于免疫调节剂和/或 HBsAg 靶向药物的患者,这些药物可作为恢复免疫反应的策略。